Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

Collaboration furthers Zenas’ vision to bring innovative immunology-based medicines to patients around the world by leveraging Bristol Myers Squibb’s long-standing expertise in immune-mediated diseases

Zenas will receive a $50 million up-front cash payment and an equity investment from Bristol Myers Squibb, along with additional potential milestone-based payments and royalties in the licensed territory

WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Zenas BioPharma, a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies, today announced that it has entered into a license and collaboration agreement with Bristol Myers Squibb Company to develop and commercialize obexelimab for autoimmune diseases in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia.

Obexelimab is an investigational bifunctional, non-cytolytic, humanized monoclonal antibody that binds CD19 and FcγRIIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells. Obexelimab is currently being studied as a subcutaneous injection in a global Phase III trial in patients with IgG4-Related Disease (IgG4-RD), a disease for which there are currently no approved treatments. The compound is also being studied in a global Phase II/III trial in patients with warm antibody Auto-Immune Hemolytic Anemia (wAIHA).

“This collaboration marks an important step forward in realizing our vision for obexelimab to benefit patients living with auto immune diseases globally,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas BioPharma. “The deeply experienced and passionate team at Bristol Myers Squibb is an ideal partner based on their proven development, regulatory and commercial capabilities in Japan and throughout the licensed territory.”

“This collaboration represents an important opportunity to address unmet needs for people living with IgG4-RD, for which there are no approved treatment options,” said Steve Sugino, Senior Vice President & General Manager, Japan, Bristol Myers Squibb. “We are excited to work with Zenas BioPharma to expand the reach of obexelimab in the licensed territory and to make an impact on the lives of patients that are waiting.”

Under the terms of the license agreement, Zenas will receive a $50 million up-front cash payment and is eligible to receive additional payments in connection with the achievement of certain development, regulatory and commercial milestones, as well as royalties on net sales of obexelimab in the licensed territory. In exchange, Bristol Myers Squibb will receive exclusive rights to develop and commercialize obexelimab in the licensed territory. In addition, Bristol Myers Squibb is making an equity investment in Zenas.

About Obexelimab

Obexelimab is an investigational Phase 3-stage, bifunctional, non-cytolytic, humanized monoclonal antibody that mimics the action of antigen-antibody complexes by binding CD19 and FcγRIIb to inhibit B-lineage cell activity. In several early-stage clinical studies, including in various autoimmune diseases, 198 subjects were treated with obexelimab. In these clinical studies, obexelimab demonstrated inhibition of B cell function without depleting the cells, resulting in encouraging treatment effect in patients with various autoimmune diseases. Zenas acquired exclusive worldwide rights to obexelimab from Xencor, Inc.

More information on the Phase 3 (INDIGO) study for the treatment of IgG4 Related Disease is available at clinicaltrials.gov: NCT05662241. More information on the Phase 3 (SApHiAre) study is available at clinicaltrials.gov: NCT05786573.

About IgG4-related disease

IgG4-RD is a chronic, immune-mediated fibro-inflammatory disease that can affect multiple organs including the major salivary glands, orbits, lacrimal glands, pancreas, biliary tree, lungs, kidneys, and retroperitoneum. Approximately 20,000 patients are diagnosed with IgG4-RD in the United States alone. Despite its increasing recognition, there remains a need for further research and effective therapeutic options for individuals living with this debilitating disease.

Across the world, the use of glucocorticoids is widely considered to be the standard of care for treating IgG4-RD. There are no approved treatment options for this condition. While commonly used, glucocorticoids and available B cell depleting therapies rarely lead to long-term, treatment-free remissions, and are associated with a high risk of toxicity in these patients. Such therapies may also impair vaccine responses, including those for SARS-CoV-2 and influenza.

About Zenas BioPharma

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology-based therapies for patients around the world. With clinical development and operations globally, Zenas is advancing a deep and balanced global portfolio of potential first- and best-in-class autoimmune therapeutics in areas of high unmet medical need while meeting the value requirements of the dynamic global healthcare environment. The company’s pipeline continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com and follow us on Twitter at @ZenasBioPharma and LinkedIn.

Investor and Media Contact:
Joe Farmer, President & COO
Zenas BioPharma
IR@zenasbio.com


Zenas BioPharma Announces Strategic License and Collaboration Agreement with Bristol Myers Squibb to Develop and Commercialize Novel Bi-Functional Antibody Obexelimab in Japan, South Korea, Taiwan, Singapore, Hong Kong and Australia

THỦ THUẬT HAY

Hướng dẫn thay đổi hình nền trên trình duyệt Cốc Cốc

Hiện nay, trình duyệt Cốc Cốc được rất nhiều người yêu thích bởi hỗ trợ nhiều chức năng hữu ích giúp người dùng truy cập Facebook bị chặn, tải video YouTube một cách dễ dàng, tự động thêm dấu tiếng Việt...

Các ứng dụng quay màn hình iOS tốt nhất

Quay màn hình iPhone, ghi màn hình iOS là cách tốt nhất để người dùng iDevice có thể gửi cho người khác clip quay từ điện thoại của mình hoặc stream màn hình chơi game từ điện thoại lên Facebook, Youtube.

Cách kiểm tra ngày mua iPhone/iPad chính xác và dễ dàng

Nếu như bạn mua máy cũ thì việc kiểm tra ngày mua của chiếc máy bạn sắp mua là rất quan trọng bởi từ đó bạn có thể biết được xem máy đã sử dụng lâu hay chưa, pin máy còn tốt hay không. Hôm nay TCN xin hướng dẫn cho bạn

Hướng dẫn tải Video YouTube về máy tính không cần phần mềm

Hôm nay Download.com.vn sẽ giới thiệu cho các bạn giải pháp mới không cần sử dụng bất kỳ phần mềm hỗ trợ nào cũng có thể dễ dàng tải Video YouTube về máy thưởng thức được.

Hướng dẫn mở công cụ Terminal (môi trường dòng lệnh) trên máy tính Mac

TCN hôm nay sẽ hướng dẫn bạn cách mở công cụ Terminal (môi trường dòng lệnh) trên máy tính Mac bằng Launchpad, Spotlight hay Finder (tên các ứng dụng trên hệ điều hành MacOS). Terminal sẽ giúp bạn truy cập vào hệ điều

ĐÁNH GIÁ NHANH

Đánh giá chi tiết xe BMW 7 Series 2019

Sang trọng và đẳng cấp là định nghĩa đơn giản nhất về BMW 7 Series 2019, đây là dòng xe biểu tượng cho sự thành công của thương hiệu BMW. Với công nghệ tiên phong bậc nhất, tiện nghi chuẩn

So kè Huawei Nova 2i và OPPO F5: Khi đồng hương chạm trán

Cuộc chiến cho các điện thoại thông minh màn hình vô cực giá cạnh tranh đã bắt đầu. Huawei Nova 2i hay OPPO F5 sẽ là siêu phẩm tầm trung đáng lựa chọn hơn?

Đánh giá chi tiết Volkswagen Passat Bluemotion giá 1,45 tỷ đồng

Tại thị trường Việt Nam, Passat là một cái tên rất mới. Volkswagen Passat chỉ mới “chân ướt chân ráo” đến thị trường Việt hồi đầu tháng 6/2016 tại triển lãm DAS Volkswagen Fest và mẫu xe này vẫn đang